Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Vaccinations01:51

Vaccinations

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma.

Journal of Cancer·2025
Same author

Systemic Therapy for Melanoma: ASCO Guideline Update Q and A.

JCO oncology practice·2023
Same author

Systemic Therapy for Melanoma: ASCO Guideline Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).

Journal of translational medicine·2023
Same author

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.

Cancer chemotherapy and pharmacology·2023
Same author

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).

Journal of translational medicine·2022
Same journal

Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model.

Expert review of vaccines·2026
Same journal

Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Whole cell and acellular pertussis vaccines - rethinking the evidence.

Expert review of vaccines·2026
Same journal

Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic.

Expert review of vaccines·2026
Same journal

Narrative shielding and prebunking: a synergistic strategy against vaccine hesitancy in pediatrics.

Expert review of vaccines·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Melanoma vaccines.

Lee B Riley1, Sanjiv S Agarwala

  • 1St Luke's Cancer Center, St Luke's Hospital and Health Network, 801 Ostrum Street, Bethlehem, PA 18015, USA. rileyl@slhn.org

Expert Review of Vaccines
|September 5, 2008
PubMed
Summary
This summary is machine-generated.

Melanoma vaccines show promise in animal models, but clinical responses in humans are poor. Novel strategies targeting immune system barriers may improve outcomes for melanoma patients.

More Related Videos

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jul 2, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Vaccine studies have shown success in preventing infections and inducing melanoma regression in animal models and humans.
  • Despite laboratory evidence of immune responses, clinical outcomes for melanoma vaccines remain unsatisfactory.

Purpose of the Study:

  • To review recent clinical trials of melanoma vaccines.
  • To highlight novel vaccine strategies for future evaluation.

Main Methods:

  • Review of recent clinical trials and scientific literature on melanoma vaccines.
  • Analysis of mechanisms hindering vaccine efficacy, including autoimmunity, dendritic cell activation, regulatory T cells, and Toll-like receptors.

Main Results:

  • While vaccine-induced immune responses are evident, clinical efficacy is limited.
  • Several mechanisms impede the development of successful melanoma vaccines.

Conclusions:

  • Understanding immune system barriers is crucial for developing effective melanoma vaccines.
  • Novel vaccine strategies, combined with adjuvant therapies, hold potential for improved clinical outcomes in melanoma treatment.